Stocks To Buy Now

Blog


BizCann Expo Brings Cannabis Business to Latin America

BizCann invites traders, vendors, entrepreneurs, regulatory authorities, investors, and cannabis enthusiasts, to attend the BizCann Expo being held in Medellin, Colombia, May 18-19, 2024. The BizCann Expo is organized by ZJ Events, bringing the businesses and professionals of the cannabis industry and its ancillaries to a common forum for networking, trading, and learning sessions.

Having spread its reach over several cities in the US, BizCann Expo is being held in Medellin, Colombia, this year to offer phenomenal trading opportunities to local businesses. Due to its favorable location, connectivity, and rich history, Medellin offers the perfect venue for hosting this networking event.

In the year 2023, the event witnessed 50+ speakers, 200+ vendors, and 5,000+ attendees who connected over two days of networking and learning at the BizCann Expo. This year the participation is expected to outgrow last year’s numbers. Industry professionals with fresh and unique ideas can leverage this expo forum to gain visibility among peers, industry giants, and investors.

Entrepreneurs and creative minds with unique business ideas can share their innovations on this platform. Several eminent industry leaders will attend the expo to discuss the latest updates and strategies for successful canna trading. Plant-touching and non-plant touching cannabis businesses will also be represented at the Expo.

The speaker sessions will be conducted by stalwarts of the cannabis industry who have years of knowledge and experience of trading in this industry. They will discuss the latest updates, regulations, challenges, and prospects that lay ahead for businesses to grow and prosper. (Applications for speaker sessions are open.)

To learn more, please visit https://ibn.fm/HqJFj

From Our Blog

Regentis Biomaterials Ltd. (NYSE American: RGNT) Builds a Manufacturing and Intellectual Property Powerhouse for the Global Cartilage Repair Market

August 13, 2026

Aging populations are pushing joint disease higher on the orthopedic agenda, with cartilage damage representing one of the field’s largest unmet needs. Current treatments have demonstrated clinical utility, but they remain difficult to deliver efficiently and economically on scale. That gap is where off-the-shelf therapies can deliver high value, and where manufacturing know-how and intellectual […]

Rotate your device 90° to view site.